Dextromethorphan + Bromhexine + Cetirizine + PCM Tablet 10mg + 8mg + 5mg + 325mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 10mg + 8mg + 5mg + 325mg

Reference Brands:

Category: Allergy Medication

-

Product Description:

This is a four-component fixed-dose combination pairing dextromethorphan (a central antitussive), bromhexine (a mucolytic), cetirizine (a second-generation antihistamine) and paracetamol (an analgesic and antipyretic). Combinations of this construction are widely marketed in India and in several South and Southeast Asian markets as multi-symptom cough and cold preparations.

A significant regulatory constraint, and the most important thing to establish before ordering. Multi-ingredient cough and cold combinations of this type face restrictions in many jurisdictions. India itself has prohibited numerous fixed-dose combinations in successive regulatory actions, and combinations pairing an antitussive with a mucolytic have attracted particular scrutiny on the grounds of pharmacological rationale. Most regulated markets — the United States, the European Union, and the majority of PIC/S member states — will not register a four-component combination of this kind.

Sourcing notes. Confirm two things in writing before proceeding. First, that the specific combination and ratio currently holds a valid manufacturing licence in India, since the permitted list changes. Second, that the destination market will register it — assume it will not unless the regulator confirms otherwise. Realistically this product suits markets that accept Indian FDC registrations, and it is not a candidate for regulated-market entry. A single-ingredient alternative is usually the better route where a regulated market is the target.